ES2519690T3 - Método de tratamiento de envenenamiento por organosfósforo - Google Patents

Método de tratamiento de envenenamiento por organosfósforo Download PDF

Info

Publication number
ES2519690T3
ES2519690T3 ES05812994.1T ES05812994T ES2519690T3 ES 2519690 T3 ES2519690 T3 ES 2519690T3 ES 05812994 T ES05812994 T ES 05812994T ES 2519690 T3 ES2519690 T3 ES 2519690T3
Authority
ES
Spain
Prior art keywords
poisoning
treatment
organosphorus
galantamine
exposure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05812994.1T
Other languages
English (en)
Inventor
Edson X. Albuquerque
Michael Adler
Edna F. R. Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
University of Maryland College Park
United States Department of the Army
Government of the United States of America
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
United States Department of the Army
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park, United States Department of the Army, Government of the United States of America filed Critical University of Maryland Baltimore
Application granted granted Critical
Publication of ES2519690T3 publication Critical patent/ES2519690T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Galantamina y agente antimuscarinico para su uso en la prevencion o el tratamiento de envenenamiento por organofósforo (OP), que comprende administrar una cantidad de galantamina de inhibición del envenenamiento por OP a un mamifero despues de la exposición a un OP y administrar ademas una cantidad eficaz de un agente antimuscarinico despues de la exposición a un OP y antes de o de manera simultanea a la galantamina.

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES05812994.1T 2004-09-24 2005-09-23 Método de tratamiento de envenenamiento por organosfósforo Expired - Lifetime ES2519690T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61312104P 2004-09-24 2004-09-24
US613121P 2004-09-24
PCT/US2005/033789 WO2006036686A2 (en) 2004-09-24 2005-09-23 Method of treating organophosphorous poisoning

Publications (1)

Publication Number Publication Date
ES2519690T3 true ES2519690T3 (es) 2014-11-07

Family

ID=36119406

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05812994.1T Expired - Lifetime ES2519690T3 (es) 2004-09-24 2005-09-23 Método de tratamiento de envenenamiento por organosfósforo
ES14002959.6T Expired - Lifetime ES2662868T3 (es) 2004-09-24 2005-09-23 Procedimiento para el tratamiento de una intoxicación por una sustancia organofosforada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14002959.6T Expired - Lifetime ES2662868T3 (es) 2004-09-24 2005-09-23 Procedimiento para el tratamiento de una intoxicación por una sustancia organofosforada

Country Status (10)

Country Link
US (2) US7888346B2 (es)
EP (2) EP1791904B1 (es)
JP (2) JP5710092B2 (es)
CN (1) CN101044200A (es)
AU (1) AU2005289808B2 (es)
CA (1) CA2583439C (es)
ES (2) ES2519690T3 (es)
IL (2) IL182048A0 (es)
PL (2) PL1791904T3 (es)
WO (1) WO2006036686A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
SG2013014170A (en) * 2012-09-19 2014-04-28 Univ Georgetown Targeted liposomes
CN103041368B (zh) * 2013-01-18 2014-04-02 新乡医学院 藻蓝蛋白在制备防治有机磷农药所致胚胎毒性的药物中的应用
US12551237B2 (en) 2017-11-01 2026-02-17 University Of Maryland, Baltimore Apparatus and method for septal punch
EP3856055B8 (en) * 2018-09-24 2024-04-17 University of Maryland, Baltimore Apparatus for septal punch

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292308A (en) * 1979-08-21 1981-09-29 Biotherapeutics, Inc. Treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents
US4550113A (en) 1982-08-19 1985-10-29 Nauchno-Issledovatelsky Institut Po Biologicheskikm Ispytaniyam Khimicheskikh Soedineny 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles
RU2057531C1 (ru) 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5480651A (en) 1992-03-16 1996-01-02 Regents Of The University Of California Composition and method for treating nicotine craving in smoking cessation
DE4342173A1 (de) 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
CA2270120A1 (en) 1996-10-28 1998-05-07 Pal Rongved Improvements in or relating to diagnostic/therapeutic agents
WO1999013864A2 (en) 1997-09-19 1999-03-25 Shire Laboratories, Inc. Solid solution beadlet
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
US6211230B1 (en) * 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures
TW558554B (en) 1999-10-29 2003-10-21 Takeda Chemical Industries Ltd Crystals of oxyiminoalkanoic acid derivative
US6617361B2 (en) 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
EP2311463A1 (en) 1999-12-10 2011-04-20 Bonnie M. Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
JP2001261652A (ja) 2000-03-21 2001-09-26 Suntory Ltd 二置換イミノヘテロサイクリック化合物
JP4969010B2 (ja) 2000-05-08 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害性ピリミジンのプロドラッグ
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
IT1317908B1 (it) 2000-09-15 2003-07-15 S I S S A Scuola Internaz Supe Muteine del frammento peptidico cgrp 1-7 e loro uso come potenziatoridei recettori nicotinici neuronali.
US6589504B1 (en) 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions
CA2429426A1 (en) 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
ATE439344T1 (de) 2000-12-22 2009-08-15 Schering Corp Muscarin-antagonisten
CN1500080A (zh) 2001-02-02 2004-05-26 ����ҩƷ��ҵ��ʽ���� 稠合杂环化合物
AU2002253929A1 (en) 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
KR100432283B1 (ko) 2001-10-27 2004-05-22 한국과학기술연구원 무스카린성 아세틸콜린 수용체에 작용하는테트라하이드로피리딘 유도체
KR100437972B1 (ko) 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
WO2003039467A2 (en) 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid.
GB0202900D0 (en) 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
WO2003092606A2 (en) * 2002-05-01 2003-11-13 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
CN1389462A (zh) 2002-07-12 2003-01-08 复旦大学 大叶蒟素及其同系物，和在制备药物组合物中的应用
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor

Also Published As

Publication number Publication date
EP2813225A1 (en) 2014-12-17
US20110144093A1 (en) 2011-06-16
CN101044200A (zh) 2007-09-26
EP1791904A4 (en) 2009-01-21
AU2005289808B2 (en) 2011-11-03
JP5710092B2 (ja) 2015-04-30
WO2006036686A3 (en) 2007-02-22
IL218241A (en) 2016-03-31
IL182048A0 (en) 2007-07-24
US8703762B2 (en) 2014-04-22
CA2583439C (en) 2016-05-10
EP2813225B1 (en) 2017-12-13
JP2008514609A (ja) 2008-05-08
PL2813225T3 (pl) 2018-11-30
AU2005289808A2 (en) 2008-07-31
IL218241A0 (en) 2012-04-30
CA2583439A1 (en) 2006-04-06
US20080070900A1 (en) 2008-03-20
EP1791904B1 (en) 2014-08-27
WO2006036686A2 (en) 2006-04-06
PL1791904T3 (pl) 2015-02-27
US7888346B2 (en) 2011-02-15
AU2005289808A1 (en) 2006-04-06
JP2013173773A (ja) 2013-09-05
EP1791904A2 (en) 2007-06-06
ES2662868T3 (es) 2018-04-10

Similar Documents

Publication Publication Date Title
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
ES2483725T3 (es) Composición básica cosmética y su uso
ES2489741T3 (es) Composición para la prevención de la aparición de acontecimientos cardiovasculares
ES2529147T3 (es) Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
AR054094A1 (es) Tratamientos de cancer
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR043258A1 (es) Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica
UY29890A1 (es) Composiciones farmacéuticas sólidas que contienen pregabalina
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CR8766A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
MX2009004204A (es) Descontaminacion de area via concentracion a bajo nivel de agente germicida.
ECSP099239A (es) Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
ECSP11010762A (es) Composición tópica para el tratamiento de queratosis actínica
ECSP088793A (es) Combinación Farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamo
ES2519690T3 (es) Método de tratamiento de envenenamiento por organosfósforo
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.